4.7 Review

The gut microbiome and microbial translocation in multiple sclerosis

期刊

CLINICAL IMMUNOLOGY
卷 183, 期 -, 页码 213-224

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2017.03.001

关键词

Multiple sclerosis; Microbiome; CNS; Gut-brain axis; Microbial translocation; Intestinal permeability

资金

  1. Acorda
  2. Bayer Pharmaceutical
  3. Biogen Idec
  4. EMD Serono
  5. Genzyme
  6. Novartis
  7. Questor
  8. Chugai
  9. Teva Neuroscience
  10. NIH NIAID Autoimmune Center of Excellence [UM1-AI110557]
  11. NIH NINDS [R01-NS080821]
  12. University of Michigan Neurology Department

向作者/读者索取更多资源

Individuals with multiple sclerosis (MS) have a distinct intestinal microbial community (microbiota) and increased low-grade translocation of bacteria from the intestines into the circulation. The observed change of intestinal bacteria in MS patients regulate immune functions involved in MS pathogenesis. These functions include: systemic and central nervous system (CNS) immunity (including peripheral regulatory T cell function), the blood-brain barrier (BBB) permeability and CNS-resident cell activity. This review discusses the MS intestinal microbiota implication on MS systemic- and CNS-immunopathology. We introduce the possible contributions of MS low-grade microbial translocation (LG-MT) to the development of MS, and end on a discussion on microbiota therapies for MS patients. (C) 2017 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据